Search All Tech Briefings

Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available. Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 152 Results

Clear All Filters

Title	Intervention	Indication	Therapeutic Area	Year	Actions
Human normal immunoglobulin for preventing primary infection in chronic lymphocytic leukaemia	Human Immunoglobulin (TAK-771)	Chronic lymphocytic leukaemia (CLL)	Haematological Cancer and Lymphomas	2024	View \| Download
Histamine dihydrochloride (Ceplene) in combination with low dose interleukin-2 as maintenance treatment for acute myeloid leukaemia	Histamine dihydrochloride (Ceplene) , Low-dose aldesluekin	Acute myeloid leukaemia (AML)	Haematological Cancer and Lymphomas	2019	View \| Download
Guadecitabine for Treatment of Naive Acute Myeloid Leukaemia	Guadecitabine (SGI-110)	Acute myeloid leukaemia (AML)	Haematological Cancer and Lymphomas	2017	View \| Download
Glofitamab with gemcitabine, oxaliplatin and rituximab for treating relapsed or refractory diffuse large B-cell lymphoma	Gemcitabine (Gemzar; gemcitabine hydrochloride) , Glofitamab (RG-6026) , Oxaliplatin , Rituximab (MabThera; Rituxan; RG 105)	Diffuse large B-cell lymphoma (DLBCL)	Haematological Cancer and Lymphomas	2022	View \| Download
Glofitamab for relapsed or refractory diffuse large B-cell lymphoma	Glofitamab (RG-6026)	Diffuse large B-cell lymphoma (DLBCL) , High grade B cell lymphoma (HGBCL) , Primary mediastinal large B-cell lymphoma (PMBCL)	Haematological Cancer and Lymphomas	2021	View \| Download
Glasdegib for Acute Myeloid Leukaemia (AML) – first line	Glasdegib (PF-04449913; glasdegib maleate)	Acute myeloid leukaemia (AML)	Haematological Cancer and Lymphomas	2017	View \| Download
Gilteritinib maintenance therapy for FLT3-ITD mutated acute myeloid leukaemia	Gilteritinib (ASP2215; Xospata; gilteritinib fumarate)	Acute myeloid leukaemia (AML)	Haematological Cancer and Lymphomas	2022	View \| Download
Gilteritinib for Relapsed or Refractory Acute Myeloid Leukaemia (AML) with an FLT3 Mutation – Second Line	Gilteritinib (ASP2215; Xospata; gilteritinib fumarate)	Acute myeloid leukaemia (AML)	Haematological Cancer and Lymphomas	2018	View \| Download
Futibatinib for treating cholangiocarcinoma with FGFR2 gene rearrangements	Futibatinib	Cholangiocarcinoma	Haematological Cancer and Lymphomas , Oncology	2023	View \| Download
Fedratinib for Myelofibrosis	Fedratinib (SAR302503)	Myelofibrosis	Haematological Cancer and Lymphomas , Haematology	2018	View \| Download